Grazoprevir/elbasvir combination therapy for HCV infection by Anaïs Vallet-Pichard, Stanislas Pol

“…Zepatier is a fixed-dose combination product coformulating MK-5172 [grazoprevir (GZR), 100 mg QD] and MK-8742 [elbasvir or (EBR) 50 mg QD]: it combines highly potent inhibitors of the HCV NS3/4A protease and NS5A replication complex, respectively. …”
Get full text

Elbasvir/grazoprevir treatment in an HCV-infected peritoneal dialysis patient by Jin Chen, Yi Li, Guisen Li, Pu Lei

Subjects: Get full text

Elbasvir/Grazoprevir for HCV Infection in Russia: A Randomized Trial by Zhdanov K, Isakov V, Burnevich E, Kizhlo S, Bakulin I, Pokrovsky V, Liang L, Hwang P, Talwani R, Haber BA, Robertson MN

“…Treatment-naive participants with chronic HCV infection were randomly assigned to receive immediate or deferred treatment with elbasvir 50 mg/grazoprevir 100 mg once daily for 12 weeks. Participants in the immediate-treatment group received elbasvir/grazoprevir for 12 weeks, and those in the deferred-treatment group received placebo for 12 weeks, followed by open-label elbasvir/grazoprevir for 12 weeks. …”
Get full text

Limited drug–drug interaction of elbasvir/grazoprevir for chronic hepatitis C by Chun-Jen Liu, Kuo-Chih Tseng, Ching-Chu Lo, I-Hao Tseng, Pin-Nan Cheng

Subjects: Get full text

Safety and efficacy of elbasvir/grazoprevir for the treatment of chronic hepatitis C: current evidence by Morikawa K, Nakamura A, Shimazaki T, Sakamoto N

“…Recently, a combination regimen consisting of the HCV nonstructural protein 5A inhibitor elbasvir (EBR) and the HCV NS3/4A protease inhibitor grazoprevir (GZR) was approved for the treatment of patients with chronic HCV and genotypes (Gts) 1 and 4 in various countries. …”
Get full text

Elbasvir/Grazoprevir: A Review of the Latest Agent in the Fight against Hepatitis C by Allison M. Bell, Jamie L. Wagner, Katie E. Barber, Kayla R. Stover

“…This review will focus on the current literature and clinical evidence supporting elbasvir/grazoprevir as first-line therapy in patients with genotypes 1 and 4 chronic hepatitis C.…”
Get full text

Repurposing potential of posaconazole and grazoprevir as inhibitors of SARS-CoV-2 helicase by Syed Hani Abidi, Nahlah Makki Almansour, Daulet Amerzhanov, Khaled S. Allemailem, Wardah Rafaqat, Mahmoud A. A. Ibrahim, Philip la Fleur, Martin Lukac, Syed Ali

“…Strong interactions of posaconazole and grazoprevir with conserved amino acids indicate that the drugs can be potent against SARS-CoV-2. …”
Get full text

Elbasvir/Grazoprevir, an Alternative in Antiviral Hepatitis C Therapy in Patients under Amiodarone Treatment by Lina Weiss, Kerstin Wustmann, Mariam Semmo, Markus Schwerzmann, Nasser Semmo

“…Here we present a treatment alternative with an elbasvir/grazoprevir regimen, based on our successful treatment of a patient under concurrent amiodarone therapy. …”
Get full text

Cost-Effectiveness of Elbasvir/Grazoprevir for the Treatment of Chronic Hepatitis C: A Systematic Review by Jinyu Liu, Min Guo, Lei Ke, Ruxu You

Subjects: Get full text

Preemptive Treatment With Elbasvir and Grazoprevir for Hepatitis C–Viremic Donor to Uninfected Recipient Kidney Transplantation by Meghan E. Sise, Ian A. Strohbehn, Donald F. Chute, Jenna Gustafson, Vivianna M. Van Deerlin, Jennifer R. Smith, Caren Gentile, David Wojciechowski, Winfred W. Williams, Nahel Elias, Raymond T. Chung

“…Conclusion: Preemptive elbasvir and grazoprevir eliminated HCV infection in HCV-naive patients who received a kidney transplant from an HCV-infected donor. …”
Get full text

P64 Concomitant proton pump inhibitor use does not reduce the efficacy of elbasvir/grazoprevir by N. Reau, M. Robertson, H.P. Feng, L. Caro, W.W. Yeh, B.Y.T. Nguyen, J. Wahl, E. Barr, P. Hwang, S.O. Klopfer

Get full text

Computational drug repurposing study elucidating simultaneous inhibition of entry and replication of novel corona virus by Grazoprevir by Santosh Kumar Behera, Nazmina Vhora, Darshan Contractor, Amit Shard, Dinesh Kumar, Kiran Kalia, Alok Jain

“…Molecular modeling followed by in-depth structural analysis clearly demonstrated that Grazoprevir interacts with the key residues of these targets. …”
Get full text

An integrated analysis of elbasvir/grazoprevir in Korean patients with hepatitis C virus genotype 1b infection by Youn Jae Lee, Jeong Heo, Do Young Kim, Woo Jin Chung, Won Young Tak, Yoon Jun Kim, Seung Woon Paik, Eungeol Sim, Susila Kulasingam, Rohit Talwani, Barbara Haber, Peggy Hwang

“…The aim of the present analysis was to evaluate the safety and efficacy of elbasvir/grazoprevir (EBR/GZR) administered for 12 weeks in Korean patients who were enrolled in international clinical trial phase 3 studies. …”
Get full text

Elbasvir/grazoprevir in women with hepatitis C virus infection taking oral contraceptives or hormone replacement therapy by Hézode C, Kwo P, Sperl J, Hwang P, Long J, Talwani R, Robertson MN, Haber BA

“…The present analysis was conducted to examine the impact of concomitant oral contraceptive pills (OCP) or hormone replacement therapy (HRT) during treatment with elbasvir (EBR)/grazoprevir (GZR) in women with HCV genotype (GT)1 or GT4 infection.Methods: This is a post hoc, integrated retrospective analysis of female participants with HCV GT1 or GT4 infection who received EBR 50 mg/GZR 100 mg once daily for 12 weeks in phase 2/3 clinical trials. …”
Get full text

Effectiveness of Elbasvir/Grazoprevir in US Veterans with Chronic Hepatitis C Virus Genotype 1b Infection by Amy Puenpatom, Yumei Cao, Xian Yu, Fasiha Kanwal, Hashem B. El-Serag, Jennifer R. Kramer

“…The aim of the present study was to assess the efficacy of elbasvir/grazoprevir in a Veterans Affairs population with chronic HCV genotype 1b infection. …”
Get full text

Reduction of Liver Fibrosis After Treatment with Elbasvir/Grazoprevir in Patients with Hepatitis C Infection in Chronic Kidney Disease on Hemodialysis, a Quasi-Experimental Study by Bayu Laksono, Nenny Agustanti, Rudi Supriyadi, Muhammad Begawan Bestari, Siti Aminah Abdurachman

Subjects: Get full text

Grazoprevir and Elbasvir in Patients with Genotype 1 Hepatitis C Virus Infection: A Comprehensive Efficacy and Safety Analysis by Yinan Yao, Ming Yue, Jie Wang, Hongbo Chen, Mei Liu, Feng Zang, Jun Li, Yun Zhang, Peng Huang, Rongbin Yu

“…One patient (<1%) receiving grazoprevir plus elbasvir alone and one (<1%) receiving grazoprevir plus elbasvir plus RBV had treatment-related serious AEs. …”
Get full text

A Single- and Multiple-Dose Study to Evaluate the Pharmacokinetics of Fixed-Dose Grazoprevir/Elbasvir in Healthy Chinese Participants by Li H, Yang Z, Zhang S, Xu L, Wei Y, Jiang J, Caro L, Feng HP, McCrea JB, Li M, Xie S, Wang J, Zhao XM, Mu S

Subjects: Get full text

Projected impact of elbasvir/grazoprevir in patients with hepatitis C virus genotype 1 and chronic kidney disease in Vietnam by Chizoba Nwankwo, Shelby L. Corman, Elamin H. Elbasha

“…Keywords: Hepatitis C, Chronic kidney disease, Economics, Elbasvir/grazoprevir…”
Get full text

Grazoprevir/elbasvir for the treatment of adults with chronic hepatitis C: a short review on the clinical evidence and place in therapy by Sulejmani N, Jafri SM

Subjects: Get full text